Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer

Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has eme...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Rep
Egile Nagusiak: BALL, DOUGLAS W., JIN, NING, XUE, PING, BHAN, SHEETAL, AHMED, SHABINA R., ROSEN, D. MARC, SCHAYOWITZ, ADAM, CLARK, DOUGLAS P., NELKIN, BARRY D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2015
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4583528/
https://ncbi.nlm.nih.gov/pubmed/26324075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4225
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak